30
Participants
Start Date
February 29, 2004
Primary Completion Date
June 30, 2011
Study Completion Date
February 28, 2017
Docetaxel
40 mg/m2, 30 minute IV infusion, Days 1 and 8, Every 21 days
Gemcitabine hydrochloride
800mg/m2, 30 minute IV infusion, Days 1 and 8, every 21 days
Northern Virginia Pelvic Surgery Assoc, Annandale
Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn
Barbara Ann Karmanos Cancer Institute, Detroit
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus
National Cancer Institute (NCI)
NIH
Robert Morris
OTHER